Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study
Main finding · Composite CV eventsResult — go to the resultHazard ratio 0.92 95 % CI 0.71–1.19Authors' conclusion
Compared to DPP4i, SGLT2i did not show superiority in the reduction of cardiovascular or renal events in CKD stage 4-5 patients.
Study context
- Population
- Patients with T2D and estimated glomerular filtration rate (eGFR) < 30 mL/min per 1.73 m² (chronic kidney disease (CKD) stage 4–5) prescribed SGLT2i or DPP-4i, 2016–2022
- Participants
- 6,730 patients
- Exposure
- SGLT2i vs DPP-4i
- SGLT2in = 1,086
- DPP4in = 5,644reference
- Outcome
- Composite CV outcome:
- CV death
- MI
- Ischemic stroke
- HF-related admission
Main finding
Composite CV events
Hazard ratio
0.92
95 % CI 0.71–1.19
SGLT2ivs DPP4i
HR 0.92 (95 % CI 0.71–1.19)
As reported in the abstract
- Composite CV event rate in both groups
- 13.2 events per 100 person-years (PYs)
Observational data: associations, not effects.
Further findings
Events per 100 PYs
| Outcome | SGLT2i | DPP4i | Subdistribution HR (95 % CI) | |
|---|---|---|---|---|
| Composite renal events (eGFR decline >50 %, doubling of serum creatinine, progression to dialysis) | 18.5 | 16.2 | 1.12 (0.91–1.38) | |
| 0.512Subdistribution hazard ratio (log scale) |
Original publication
Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study. Diabetes Res Clin Pract. Published 26 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →